The EuroSIDA study: 25 years of scientific achievements

K. Laut*, O. Kirk, J. Rockstroh, A. Phillips, B. Ledergerber, J. Gatell, B. Gazzard, A. Horban, I. Karpov, M. Losso, A. d’Arminio Monforte, C. Pedersen, M. Ristola, P. Reiss, A. U. Scherrer, S. de Wit, I. Aho, L. D. Rasmussen, V. Svedhem, G. WandelerC. Pradier, N. Chkhartishvili, R. Matulionyte, C. Oprea, J. D. Kowalska, J. Begovac, J. M. Miró, G. Guaraldi, R. Paredes, D. Raben, D. Podlekareva, L. Peters, J. D. Lundgren, A. Mocroft

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The EuroSIDA study was initiated in 1994 and follows adult people living with HIV (PLHIV) in 100 collaborating clinics across 35 countries covering all European regions, Israel and Argentina. The study aims to study the long-term virological, immunological and clinical outcomes of PLHIV and to monitor temporal changes and regional differences in outcomes across Europe. Annually collected data include basic demographic characteristics, information on AIDS- and non-AIDS-related clinical events, and details about antiretroviral therapy (ART), hepatitis C treatment and other medications, in addition to a range of laboratory values. The summer 2016 data set held data from a total of 23 071 individuals contributing 174 481 person-years of follow-up, while EuroSIDA’s unique plasma repository held over 160 000 samples. Over the past 25 years, close to 300 articles have been published in peer-reviewed journals (h-index 52), covering a range of scientific focus areas, including monitoring of clinical and virological outcomes, ART uptake, efficacy and adverse events, the influence of hepatitis virus coinfection, variation in the quality of HIV care and management across settings and regions, and biomarker research. Recognizing that there remain unresolved issues in the clinical care and management of PLHIV in Europe, EuroSIDA was one of the cohorts to found The International Cohort Consortium of Infectious Disease (RESPOND) cohort consortium on infectious diseases in 2017. In celebration of the EuroSIDA study’s 25th anniversary, this article aims to summarize key scientific findings and outline current and future scientific focus areas.

Original languageEnglish
JournalHIV Medicine
Volume21
Issue number2
Pages (from-to)71-83
ISSN1464-2662
DOIs
Publication statusPublished - Feb 2020

Fingerprint

HIV
Hepatitis Viruses
Quality of Health Care
Israel
Hepatitis C
Coinfection
Acquired Immunodeficiency Syndrome
Research
Datasets

Keywords

  • AIDS
  • cohort studies
  • Europe
  • HIV
  • surveillance

Cite this

Laut, K., Kirk, O., Rockstroh, J., Phillips, A., Ledergerber, B., Gatell, J., ... Mocroft, A. (2020). The EuroSIDA study: 25 years of scientific achievements. HIV Medicine, 21(2), 71-83. https://doi.org/10.1111/hiv.12810
Laut, K. ; Kirk, O. ; Rockstroh, J. ; Phillips, A. ; Ledergerber, B. ; Gatell, J. ; Gazzard, B. ; Horban, A. ; Karpov, I. ; Losso, M. ; d’Arminio Monforte, A. ; Pedersen, C. ; Ristola, M. ; Reiss, P. ; Scherrer, A. U. ; de Wit, S. ; Aho, I. ; Rasmussen, L. D. ; Svedhem, V. ; Wandeler, G. ; Pradier, C. ; Chkhartishvili, N. ; Matulionyte, R. ; Oprea, C. ; Kowalska, J. D. ; Begovac, J. ; Miró, J. M. ; Guaraldi, G. ; Paredes, R. ; Raben, D. ; Podlekareva, D. ; Peters, L. ; Lundgren, J. D. ; Mocroft, A. / The EuroSIDA study : 25 years of scientific achievements. In: HIV Medicine. 2020 ; Vol. 21, No. 2. pp. 71-83.
@article{47afa123f2534a11aed64d6908b01707,
title = "The EuroSIDA study: 25 years of scientific achievements",
abstract = "The EuroSIDA study was initiated in 1994 and follows adult people living with HIV (PLHIV) in 100 collaborating clinics across 35 countries covering all European regions, Israel and Argentina. The study aims to study the long-term virological, immunological and clinical outcomes of PLHIV and to monitor temporal changes and regional differences in outcomes across Europe. Annually collected data include basic demographic characteristics, information on AIDS- and non-AIDS-related clinical events, and details about antiretroviral therapy (ART), hepatitis C treatment and other medications, in addition to a range of laboratory values. The summer 2016 data set held data from a total of 23 071 individuals contributing 174 481 person-years of follow-up, while EuroSIDA’s unique plasma repository held over 160 000 samples. Over the past 25 years, close to 300 articles have been published in peer-reviewed journals (h-index 52), covering a range of scientific focus areas, including monitoring of clinical and virological outcomes, ART uptake, efficacy and adverse events, the influence of hepatitis virus coinfection, variation in the quality of HIV care and management across settings and regions, and biomarker research. Recognizing that there remain unresolved issues in the clinical care and management of PLHIV in Europe, EuroSIDA was one of the cohorts to found The International Cohort Consortium of Infectious Disease (RESPOND) cohort consortium on infectious diseases in 2017. In celebration of the EuroSIDA study’s 25th anniversary, this article aims to summarize key scientific findings and outline current and future scientific focus areas.",
keywords = "AIDS, cohort studies, Europe, HIV, surveillance",
author = "K. Laut and O. Kirk and J. Rockstroh and A. Phillips and B. Ledergerber and J. Gatell and B. Gazzard and A. Horban and I. Karpov and M. Losso and {d’Arminio Monforte}, A. and C. Pedersen and M. Ristola and P. Reiss and Scherrer, {A. U.} and {de Wit}, S. and I. Aho and Rasmussen, {L. D.} and V. Svedhem and G. Wandeler and C. Pradier and N. Chkhartishvili and R. Matulionyte and C. Oprea and Kowalska, {J. D.} and J. Begovac and Mir{\'o}, {J. M.} and G. Guaraldi and R. Paredes and D. Raben and D. Podlekareva and L. Peters and Lundgren, {J. D.} and A. Mocroft",
year = "2020",
month = "2",
doi = "10.1111/hiv.12810",
language = "English",
volume = "21",
pages = "71--83",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "2",

}

Laut, K, Kirk, O, Rockstroh, J, Phillips, A, Ledergerber, B, Gatell, J, Gazzard, B, Horban, A, Karpov, I, Losso, M, d’Arminio Monforte, A, Pedersen, C, Ristola, M, Reiss, P, Scherrer, AU, de Wit, S, Aho, I, Rasmussen, LD, Svedhem, V, Wandeler, G, Pradier, C, Chkhartishvili, N, Matulionyte, R, Oprea, C, Kowalska, JD, Begovac, J, Miró, JM, Guaraldi, G, Paredes, R, Raben, D, Podlekareva, D, Peters, L, Lundgren, JD & Mocroft, A 2020, 'The EuroSIDA study: 25 years of scientific achievements', HIV Medicine, vol. 21, no. 2, pp. 71-83. https://doi.org/10.1111/hiv.12810

The EuroSIDA study : 25 years of scientific achievements. / Laut, K.; Kirk, O.; Rockstroh, J.; Phillips, A.; Ledergerber, B.; Gatell, J.; Gazzard, B.; Horban, A.; Karpov, I.; Losso, M.; d’Arminio Monforte, A.; Pedersen, C.; Ristola, M.; Reiss, P.; Scherrer, A. U.; de Wit, S.; Aho, I.; Rasmussen, L. D.; Svedhem, V.; Wandeler, G.; Pradier, C.; Chkhartishvili, N.; Matulionyte, R.; Oprea, C.; Kowalska, J. D.; Begovac, J.; Miró, J. M.; Guaraldi, G.; Paredes, R.; Raben, D.; Podlekareva, D.; Peters, L.; Lundgren, J. D.; Mocroft, A.

In: HIV Medicine, Vol. 21, No. 2, 02.2020, p. 71-83.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - The EuroSIDA study

T2 - 25 years of scientific achievements

AU - Laut, K.

AU - Kirk, O.

AU - Rockstroh, J.

AU - Phillips, A.

AU - Ledergerber, B.

AU - Gatell, J.

AU - Gazzard, B.

AU - Horban, A.

AU - Karpov, I.

AU - Losso, M.

AU - d’Arminio Monforte, A.

AU - Pedersen, C.

AU - Ristola, M.

AU - Reiss, P.

AU - Scherrer, A. U.

AU - de Wit, S.

AU - Aho, I.

AU - Rasmussen, L. D.

AU - Svedhem, V.

AU - Wandeler, G.

AU - Pradier, C.

AU - Chkhartishvili, N.

AU - Matulionyte, R.

AU - Oprea, C.

AU - Kowalska, J. D.

AU - Begovac, J.

AU - Miró, J. M.

AU - Guaraldi, G.

AU - Paredes, R.

AU - Raben, D.

AU - Podlekareva, D.

AU - Peters, L.

AU - Lundgren, J. D.

AU - Mocroft, A.

PY - 2020/2

Y1 - 2020/2

N2 - The EuroSIDA study was initiated in 1994 and follows adult people living with HIV (PLHIV) in 100 collaborating clinics across 35 countries covering all European regions, Israel and Argentina. The study aims to study the long-term virological, immunological and clinical outcomes of PLHIV and to monitor temporal changes and regional differences in outcomes across Europe. Annually collected data include basic demographic characteristics, information on AIDS- and non-AIDS-related clinical events, and details about antiretroviral therapy (ART), hepatitis C treatment and other medications, in addition to a range of laboratory values. The summer 2016 data set held data from a total of 23 071 individuals contributing 174 481 person-years of follow-up, while EuroSIDA’s unique plasma repository held over 160 000 samples. Over the past 25 years, close to 300 articles have been published in peer-reviewed journals (h-index 52), covering a range of scientific focus areas, including monitoring of clinical and virological outcomes, ART uptake, efficacy and adverse events, the influence of hepatitis virus coinfection, variation in the quality of HIV care and management across settings and regions, and biomarker research. Recognizing that there remain unresolved issues in the clinical care and management of PLHIV in Europe, EuroSIDA was one of the cohorts to found The International Cohort Consortium of Infectious Disease (RESPOND) cohort consortium on infectious diseases in 2017. In celebration of the EuroSIDA study’s 25th anniversary, this article aims to summarize key scientific findings and outline current and future scientific focus areas.

AB - The EuroSIDA study was initiated in 1994 and follows adult people living with HIV (PLHIV) in 100 collaborating clinics across 35 countries covering all European regions, Israel and Argentina. The study aims to study the long-term virological, immunological and clinical outcomes of PLHIV and to monitor temporal changes and regional differences in outcomes across Europe. Annually collected data include basic demographic characteristics, information on AIDS- and non-AIDS-related clinical events, and details about antiretroviral therapy (ART), hepatitis C treatment and other medications, in addition to a range of laboratory values. The summer 2016 data set held data from a total of 23 071 individuals contributing 174 481 person-years of follow-up, while EuroSIDA’s unique plasma repository held over 160 000 samples. Over the past 25 years, close to 300 articles have been published in peer-reviewed journals (h-index 52), covering a range of scientific focus areas, including monitoring of clinical and virological outcomes, ART uptake, efficacy and adverse events, the influence of hepatitis virus coinfection, variation in the quality of HIV care and management across settings and regions, and biomarker research. Recognizing that there remain unresolved issues in the clinical care and management of PLHIV in Europe, EuroSIDA was one of the cohorts to found The International Cohort Consortium of Infectious Disease (RESPOND) cohort consortium on infectious diseases in 2017. In celebration of the EuroSIDA study’s 25th anniversary, this article aims to summarize key scientific findings and outline current and future scientific focus areas.

KW - AIDS

KW - cohort studies

KW - Europe

KW - HIV

KW - surveillance

U2 - 10.1111/hiv.12810

DO - 10.1111/hiv.12810

M3 - Journal article

C2 - 31647187

AN - SCOPUS:85074598930

VL - 21

SP - 71

EP - 83

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 2

ER -

Laut K, Kirk O, Rockstroh J, Phillips A, Ledergerber B, Gatell J et al. The EuroSIDA study: 25 years of scientific achievements. HIV Medicine. 2020 Feb;21(2):71-83. https://doi.org/10.1111/hiv.12810